MIT Professor Pentelute Takes Helm of Decoy Therapeutics' Scientific Advisory Board
Event summary
- Brad Pentelute, MIT chemistry professor, appointed Chair of Decoy Therapeutics' Scientific Advisory Board on May 26, 2026.
- Pentelute replaces Shahin Gharakhanian, who led the SAB during a foundational period for the company.
- Pentelute will guide Decoy's IMP3ACT™ platform and Designable Multi-Antivirals (D-MAVs™) pipeline.
- Decoy Therapeutics is a clinical-stage biotech pioneering antivirals targeting shared viral mechanisms.
The big picture
Decoy Therapeutics is positioning itself at the forefront of a shift in antiviral medicine, moving away from the traditional one-virus, one-drug approach. The appointment of Brad Pentelute, a leader in peptide synthesis and protein engineering, underscores the company's commitment to leveraging cutting-edge technology to target shared viral mechanisms. This strategic move comes as the biotech industry increasingly focuses on developing broad-spectrum antivirals to combat emerging viral threats.
What we're watching
- Scientific Direction
- How Pentelute's leadership will accelerate Decoy's IMP3ACT platform and D-MAVs pipeline toward clinical development.
- Technological Integration
- Whether the combination of peptide chemistry, rapid synthesis, and AI-enabled design can deliver on Decoy's multi-antiviral vision.
- Market Differentiation
- The pace at which Decoy can establish its D-MAVs as a viable alternative to the traditional one-virus, one-drug model.
Related topics